As of November 4, 2026, Enanta Pharmaceuticals Inc. is a publicly traded company (Nasdaq: ENTA); its largest reported holder is Janus Henderson, with 12.1% on Schedule 13G of November 7, 2025, then Dapice Joshua J. (9.8%). The largest insider holding is Jay R. Luly, the chief executive and president, with 871,871 shares (3.0% of shares outstanding), per Form 4 of February 13, 2026 (Schedule 13G, November 7, 2025).
Is this your company?
About to sign with, pay or invest in Enanta Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Enanta Pharmaceuticals Inc. a real, registered company?
- Enanta Pharmaceuticals Inc files with the SEC under CIK 1177648 (its SEC filings).
- Its shares are listed under the ticker ENTA on Nasdaq (SEC company record).
- business address in Watertown, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ENANTA PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-04).
- Leadership changes: the latest reported is Tara L. Kieffer, Chief Operating Officer (Form 8-K filed 2026-10-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Enanta Pharmaceuticals Inc.'s owners and officers?
Enanta Pharmaceuticals Inc.: business address in Watertown, Massachusetts; industry Pharmaceutical Preparations (Form D, 2026-10-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock Portfolio Management LLC | 5.4% |
| Schedule 13G/A, 2026-08-14 | Farallon Capital Management, L.L.C. | 8.3% |
| Schedule 13G/A, 2026-08-14 | Deep Track Capital, LP | 4.97% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-13 | Deep Track Capital, LP | 6.78% |
| Schedule 13G/A, 2026-02-05 | Dapice Joshua J. | 9.8% |
| Schedule 13G/A, 2026-01-20 | Integrated Core Strategies (US) LLC | 2.3% |
| Schedule 13G/A, 2025-11-13 | Millennium Management LLC | 4.1% |
| Schedule 13G, 2025-11-07 | Janus Henderson Group PLC | 12.1% |
| Schedule 13G, 2025-10-09 | Deep Track Capital, LP | 5.33% |
Questions about who owns Enanta Pharmaceuticals Inc.
Who owns Enanta Pharmaceuticals Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Enanta Pharmaceuticals Inc.: Janus Henderson Group PLC (12.1%, Schedule 13G, filed 2025-11-07), Dapice Joshua J. (9.8%, Schedule 13G/A, filed 2026-02-05), Farallon Capital Management, L.L.C. (8.3%, Schedule 13G/A, filed 2026-08-14) and Blackrock Portfolio Management LLC (5.4%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Enanta Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Enanta Pharmaceuticals Inc. on this page are Janus Henderson Group PLC (12.1%), Dapice Joshua J. (9.8%) and Farallon Capital Management, L.L.C. (8.3%).
When did Janus Henderson Group PLC buy into Enanta Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G, filed 2025-11-07, reporting 12.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Enanta Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Enanta Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enanta Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-28 | Tara L. Kieffer | Chief Operating Officer | appointed |
Which insiders own Enanta Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 871,871 shares (3.0% of shares outstanding) (Form 4, 2026-02-13).
- , the chief scientific officer: 374,854 shares (1.3% of shares outstanding) (Form 4, 2026-02-13).
- , the chief fin. and admin officer: 95,884 shares (0.33% of shares outstanding) (Form 4, 2025-02-14).
- , the chief business officer: 41,634 shares (0.14% of shares outstanding) (Form 4, 2026-02-13).
- , the chief product strategy officer: 33,925 shares (0.12% of shares outstanding) (Form 4, 2026-02-13).
Shares outstanding: 29,125,402 as of 2026-08-07, from the company's latest SEC cover page.
How much has Enanta Pharmaceuticals Inc. raised?
No fundraising or offering filing from Enanta Pharmaceuticals Inc. is on file with us.
Keep reading
More on Enanta Pharmaceuticals Inc. and the records around it.
Enanta Pharmaceuticals Inc. elsewhere on the record
- Leadership changes Oct 2026
- 5%+ stake filings Oct 2026
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Aug 2026), InflaRx N.V. (Aug 2026), Savara Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/enanta-pharmaceuticals